RNAC - Cartesian Therapeutics, Inc.

9.52
-0.590   -6.197%

Share volume: 163,371
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$10.11
-0.59
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 50%
Dept financing 25%
Liquidity 75%
Performance 35%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.80%
1 Month
-46.85%
3 Months
-43.47%
6 Months
-57.16%
1 Year
-31.95%
2 Year
789.72%
Key data
Stock price
$9.52
P/E Ratio 
0.00
DAY RANGE
$9.33 - $11.49
EPS 
$0.23
52 WEEK RANGE
$9.02 - $41.21
52 WEEK CHANGE
-$41.67
MARKET CAP 
455.181 M
YIELD 
N/A
SHARES OUTSTANDING 
21.382 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
2.30
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$147,719
AVERAGE 30 VOLUME 
$118,323
Company detail
CEO: Carsten Brunn
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.

Recent news
loading